Christoph Licht

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9177024/publications.pdf

Version: 2024-02-01

155 papers	7,832 citations	66343 42 h-index	53230 85 g-index
158 all docs	158 docs citations	158 times ranked	7364 citing authors

#	Article	IF	Citations
1	Reversal of Stroke-Like Episodes With L-Arginine and Meticulous Perioperative Management of Renal Transplantation in a Patient With Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome. Case Report. Neurohospitalist, The, 2022, 12, 67-73.	0.8	4
2	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
3	Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatric Nephrology, 2022, 37, 1479-1493.	1.7	8
4	Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight, 2022, 7, .	5.0	13
5	FC 115: Long-Term Outcomes in Eculizumab-Treated Kidney Transplant Patients Enrolled in the Global Atypical Haemolytic Uraemic Syndrome Registry. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
6	Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. Journal of Allergy and Clinical Immunology, 2021, 147, 749-753.e2.	2.9	6
7	Canadian Association of Paediatric Nephrologists COVID-19 Rapid Response: Guidelines for Management of Acute Kidney Injury in Children. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812199013.	1.1	2
8	Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children. , 2021, , 1-31.		1
9	Hemodiafiltration maintains a sustained improvement in blood pressure compared to conventional hemodialysis in childrenâ€"the HDF, heart and height (3H) study. Pediatric Nephrology, 2021, 36, 2393-2403.	1.7	9
10	Inherited Kidney Complement Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 942-956.	4.5	34
11	Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration. Kidney International Reports, 2021, 6, 1003-1014.	0.8	1
12	Cell Biological Responses after Shiga Toxin-1 Exposure to Primary Human Glomerular Microvascular Endothelial Cells from Pediatric and Adult Origin. International Journal of Molecular Sciences, 2021, 22, 5615.	4.1	2
13	MO107CLINICAL CHARACTERISTICS OF A PATIENT POPULATION WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME AND MALIGNANT HYPERTENSION: THE GLOBAL AHUS REGISTRY ANALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
14	Identification of a Locus on the X Chromosome Linked to Familial Membranous Nephropathy. Kidney International Reports, 2021, 6, 1669-1676.	0.8	3
15	Bloodâ€"brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study. Blood Advances, 2021, 5, 4211-4218.	5.2	4
16	Hemodiafiltration Is Associated With Reduced Inflammation and Increased Bone Formation Compared With Conventional Hemodialysis in Children: The HDF, Hearts and Heights (3H) Study. Kidney International Reports, 2021, 6, 2358-2370.	0.8	11
17	Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110087.	1.1	18
18	The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS. Microorganisms, 2021, 9, 2157.	3.6	6

#	Article	IF	Citations
19	Implementing a fluid volume management program to decrease intra-dialytic hypotensive events in a paediatric in-centre haemodialysis unit: a quality improvement project. Pediatric Nephrology, 2021, , 1.	1.7	0
20	Shiga Toxin 2a Induces NETosis via NOX-Dependent Pathway. Biomedicines, 2021, 9, 1807.	3.2	4
21	Helping nephrologists find answers: hyperinsulinism and tubular dysfunction: Questions. Pediatric Nephrology, 2020, 35, 253-255.	1.7	0
22	Helping nephrologists find answers: hyperinsulinism and tubular dysfunction: Answers. Pediatric Nephrology, 2020, 35, 257-260.	1.7	0
23	Association of outcomes in acute flaccid myelitis with identification of enterovirus at presentation: a Canadian, nationwide, longitudinal study. The Lancet Child and Adolescent Health, 2020, 4, 828-836.	5.6	9
24	Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney International Reports, 2020, 5, 2313-2324.	0.8	14
25	Hemodialysis Catheters in Infants: AÂRetrospective Single-Center Cohort Study. Journal of Vascular and Interventional Radiology, 2020, 31, 778-786.	0.5	8
26	Primary Human Derived Blood Outgrowth Endothelial Cells: An Appropriate In Vitro Model to Study Shiga Toxin Mediated Damage of Endothelial Cells. Toxins, 2020, 12, 483.	3.4	4
27	Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H. Frontiers in Immunology, 2020, 11, 1833.	4.8	19
28	Vascular endothelial cells evade complementâ€mediated membrane injury via Weibelâ€Palade body mobilization. Journal of Thrombosis and Haemostasis, 2020, 18, 1484-1494.	3.8	12
29	Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. Kidney International Reports, 2020, 5, 1161-1171.	0.8	12
30	Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435811989722.	1.1	5
31	Peripheral Venous Access for Collection of Immune Effector Cells and Hematopoietic Stem Cells Is Feasible and Safe in Older Children and Young Adult Patients. Blood, 2020, 136, 19-20.	1.4	0
32	Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. CKJ: Clinical Kidney Journal, 2019, 12, 196-205.	2.9	16
33	SP022IMPAIRED ENDOTHELIAL CELL MIGRATION: NEW INSIGHTS INTO THE MECHANISMS OF COMPLEMENT-MEDIATED ENDOTHELIAL CELL INJURY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
34	Renal replacement therapy in the management of intoxications in children: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) workgroup. Pediatric Nephrology, 2019, 34, 2427-2448.	1.7	14
35	An upfront immunomodulatory therapy protocol for pediatric opsoclonusâ€myoclonus syndrome. Pediatric Blood and Cancer, 2019, 66, e27776.	1.5	16
36	Effects of Hemodiafiltration versus Conventional Hemodialysis in Children with ESKD: The HDF, Heart and Height Study. Journal of the American Society of Nephrology: JASN, 2019, 30, 678-691.	6.1	60

#	Article	IF	Citations
37	Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrology, 2019, 20, 125.	1.8	77
38	The Role of Complement in the Pathogenesis of HUS and the TMA Spectrum Disorders. Current Pediatrics Reports, 2019, 7, 1-11.	4.0	3
39	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney International Reports, 2019, 4, 434-446.	0.8	59
40	Is there a case for eculizumab for pediatric renal transplantation?. Pediatric Transplantation, 2018, 22, e13128.	1.0	0
41	Relative antibacterial functions of complement and NETs: NETs trap and complement effectively kills bacteria. Molecular Immunology, 2018, 97, 71-81.	2.2	33
42	Pathogenesis and treatment of ANCA-associated vasculitisâ€”a role for complement. Pediatric Nephrology, 2018, 33, 1-11.	1.7	19
43	The role of von Willebrand factor in thrombotic microangiopathy. Pediatric Nephrology, 2018, 33, 1297-1307.	1.7	8
44	Neonatal stroke and haematuria: Answers. Pediatric Nephrology, 2018, 33, 807-811.	1.7	0
45	Neonatal stroke and haematuria: Questions. Pediatric Nephrology, 2018, 33, 805-806.	1.7	1
46	Long-term Eculizumab Therapy in a Child With Refractory Immune Complexâ€“Mediated Membranoproliferative Glomerulonephritis. Kidney International Reports, 2018, 3, 482-485.	0.8	3
47	Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency. CKJ: Clinical Kidney Journal, 2018, 11, 310-314.	2.9	12
48	Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genetics in Medicine, 2018, 20, 435-443.	2.4	404
49	FP250FACIT-FATIGUE SCORES IN ADULT PATIENTS AT ENROLLMENT INTO THE GLOBAL AHUS REGISTRY. Nephrology Dialysis Transplantation, 2018, 33, i114-i114.	0.7	1
50	The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik, 2018, 30, 400-409.	0.2	33
51	Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR. Journal of Clinical Medicine, 2018, 7, 324.	2.4	5
52	Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings. Pediatric Nephrology, 2018, 33, 1773-1780.	1.7	32
53	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	13.7	132
54	Effect of haemodiafiltration vs conventional haemodialysis on growth and cardiovascular outcomes in children â€“ the HDF, heart and height (3H) study. BMC Nephrology, 2018, 19, 199.	1.8	22

#	Article	IF	Citations
55	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andÂoutcome. Kidney International, 2018, 94, 408-418.	5.2	117
56	C3 Glomerulopathy. Pediatric Nephrology, 2017, 32, 43-57.	1.7	67
57	Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. Journal of Child Neurology, 2017, 32, 301-307.	1.4	50
58	Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with highâ€risk leukemia. Transfusion, 2017, 57, 1536-1542.	1.6	12
59	Short, frequent, 5-days-per-week, in-center hemodialysis versus 3-days-per week treatment: a randomized crossover pilot trial through the Midwest Pediatric Nephrology Consortium. Pediatric Nephrology, 2017, 32, 1423-1432.	1.7	6
60	Plastic bronchitis: a rare complication of long-term haemodialysis catheter placement in a child. Pediatric Nephrology, 2017, 32, 1635-1638.	1.7	1
61	Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells. Kidney International Reports, 2017, 2, 66-75.	0.8	29
62	SP149ECULIZUMAB TREATMENT OF SHIGA TOXIN ESCHERICHIA COLI HEMOLYTIC UREMIC SYNDROME. Nephrology Dialysis Transplantation, 2017, 32, iii154-iii154.	0.7	0
63	GlomerulÃre Erkrankungen. , 2017, , 69-123.		1
64	Comparison of two apheresis systems for autologous stem cell collections in pediatric oncology patients. Transfusion, 2017, 57, 122-130.	1.6	21
65	NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Frontiers in Immunology, 2016, 7, 137.	4.8	123
66	Von Willebrand factor regulates complement on endothelial cells. Kidney International, 2016, 90, 123-134.	5.2	53
67	C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Pediatric Nephrology, 2016, 31, 2079-2086.	1.7	35
68	The alternative pathway of complement and the thrombotic microangiopathies. Transfusion and Apheresis Science, 2016, 54, 220-231.	1.0	13
69	Impact of fill volume on ultrafiltration with icodextrin in children on chronic peritoneal dialysis. Pediatric Nephrology, 2016, 31, 1673-1679.	1.7	14
70	FAT1 mutations cause a glomerulotubular nephropathy. Nature Communications, 2016, 7, 10822.	12.8	99
71	An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet Journal of Rare Diseases, 2016, 11, 154.	2.7	22
72	An atypical case of acute kidney injury: Questions. Pediatric Nephrology, 2016, 31, 917-917.	1.7	1

#	Article	IF	Citations
73	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	4.5	53
74	Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International, 2016, 89, 701-711.	5.2	210
75	Membranoproliferative and C3-Mediated GN in Children. , 2016, , 1035-1053.		2
76	CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatric Nephrology, 2016, 31, 157-161.	1.7	18
77	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	1.7	445
78	An atypical case of acute kidney injury: Answers. Pediatric Nephrology, 2016, 31, 919-921.	1.7	1
79	C3 Glomerulopathies. , 2016, , 633-649.		0
80	The Role of Complement in Disease. , 2016, , 583-596.		1
81	The global aHUS registry: methodology and initial patient characteristics. BMC Nephrology, 2015, 16, 207.	1.8	52
82	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	5.2	342
83	Eculizumab hepatotoxicity in pediatric aHUS. Pediatric Nephrology, 2015, 30, 775-781.	1.7	39
84	Rare diseases and effective treatments: are we delivering?. Lancet, The, 2015, 385, 750-752.	13.7	46
85	The Impact of Hypoparathyroidism Treatment on the Kidney in Children: Long-Term Retrospective Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4106-4113.	3.6	40
86	Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 2252-2252.	1.4	2
87	Membranoproliferative and C3-Mediated GN in Children. , 2015, , 1-22.		0
88	The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 4640-4640.	1.4	0
89	Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantationâ€“Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2014, 20, 518-525.	2.0	218
90	Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options. Pediatric Nephrology, 2014, 29, 779-792.	1.7	36

#	Article	IF	Citations
91	Treatment of DEAP-HUSâ€"seeking the best strategy. Pediatric Nephrology, 2014, 29, 941-942.	1.7	2
92	Successful treatment of DEAP-HUS with eculizumab. Pediatric Nephrology, 2014, 29, 841-851.	1.7	36
93	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1967-1978.	1.7	95
94	Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. Seminars in Thrombosis and Hemostasis, 2014, 40, 444-464.	2.7	117
95	Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update. Blood, 2014, 124, 4986-4986.	1.4	2
96	Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry. Blood, 2014, 124, 4204-4204.	1.4	0
97	Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience. Blood, 2014, 124, 4186-4186.	1.4	0
98	An update on the pathomechanisms and future therapies of Alport syndrome. Pediatric Nephrology, 2013, 28, 1025-1036.	1.7	27
99	The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2013, 28, 939-949.	1.7	21
100	Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy. Journal of Immunology, 2013, 191, 2184-2193.	0.8	59
101	Substantial practice variation exists in the management of childhood nephrotic syndrome. Pediatric Nephrology, 2013, 28, 2289-2298.	1.7	33
102	Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric Nephrology, 2013, 28, 5-11.	1.7	118
103	Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Molecular Immunology, 2013, 54, 84-88.	2.2	23
104	Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nature Genetics, 2013, 45, 1375-1379.	21.4	158
105	Eculizumab in Atypical Hemolyticâ€"Uremic Syndrome. New England Journal of Medicine, 2013, 369, 1377-1380.	27.0	61
106	Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood, 2013, 122, 2003-2007.	1.4	237
107	Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab. Blood, 2013, 122, 2186-2186.	1.4	1
108	Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS). Blood, 2013, 122, 2191-2191.	1.4	1

#	Article	IF	Citations
109	Eculizumab and Refractory Membranoproliferative Glomerulonephritis. New England Journal of Medicine, 2012, 366, 1165-1166.	27.0	113
110	Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney International, 2012, 81, 779-783.	5.2	113
111	Trends in pediatric primary membranoproliferative glomerulonephritis costs and complications. Pediatric Nephrology, 2012, 27, 2243-2250.	1.7	6
112	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney International, 2012, 81, 494-501.	5.2	275
113	Antibody Mediated Rejection Associated With Complement Factor Hâ€“Related Protein 3/1 Deficiency Successfully Treated With Eculizumab. American Journal of Transplantation, 2012, 12, 2546-2553.	4.7	61
114	Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.. Blood, 2012, 120, 2085-2085.	1.4	1
115	Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results. Blood, 2012, 120, 985-985.	1.4	28
116	Genetics of Proteinuria: An Overview of Gene Mutations Associated with Nonsyndromic Proteinuric Glomerulopathies. Advances in Chronic Kidney Disease, 2011, 18, 273-289.	1.4	15
117	aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric Nephrology, 2011, 26, 41-57.	1.7	122
118	Pandemic H1N1 influenza A infection and (atypical) HUSâ€”more than just another trigger?. Pediatric Nephrology, 2011, 26, 3-5.	1.7	46
119	Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy. Pediatric Nephrology, 2011, 26, 979-985.	1.7	8
120	Nocturnal enuresis in adolescents with anorexia nervosa: Prevalence, potential causes, and pathophysiology. International Journal of Eating Disorders, 2011, 44, 349-355.	4.0	15
121	Hemolytic Uremic Syndrome. , 2011, , 277-297.		1
122	Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,. Blood, 2011, 118, 3303-3303.	1.4	3
123	Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS). Blood, 2011, 118, 4772-4772.	1.4	3
124	Severe atypical HUS caused by CFH S1191Lâ€”case presentation and review of treatment options. Pediatric Nephrology, 2010, 25, 97-104.	1.7	27
125	DEAP-HUS: Deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatric Nephrology, 2010, 25, 2009-2019.	1.7	72
126	Hemolytic uremic syndrome caused by Bordetella pertussis infection. Pediatric Nephrology, 2010, 25, 1361-1364.	1.7	19

#	Article	IF	Citations
127	Behavioural abnormalities in children with nephrotic syndrome--an underappreciated complication of a standard treatment?. Nephrology Dialysis Transplantation, 2010, 25, 2397-2399.	0.7	18
128	Treatment of paediatric vancomycin intoxication: a case report and review of the literature. CKJ: Clinical Kidney Journal, 2010, 3, 260-264.	2.9	7
129	Osteopontin Mediates Citrobacter rodentium-Induced Colonic Epithelial Cell Hyperplasia and Attaching-Effacing Lesions. American Journal of Pathology, 2010, 177, 1320-1332.	3.8	20
130	Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thrombosis and Haemostasis, 2009, 101, 271-278.	3.4	58
131	C3 deposition glomerulopathy due to a functional Factor H defect. Kidney International, 2009, 75, 1230-1234.	5.2	79
132	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology, 2009, 24, 687-696.	1.7	315
133	Remission of resistant MPGN type I with mycophenolate mofetil and steroids. Pediatric Nephrology, 2009, 24, 597-600.	1.7	14
134	Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Molecular Immunology, 2009, 46, 2801-2807.	2.2	44
135	Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood, 2009, 114, 4538-4545.	1.4	70
136	Membranoproliferative Glomerulonephritis. , 2009, , 783-797.		2
137	Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thrombosis and Haemostasis, 2009, 101, 271-8.	3.4	26
138	Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood, 2008, 111, 1512-1514.	1.4	332
139	Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrology Dialysis Transplantation, 2008, 24, 731-734.	0.7	40
140	Membranoproliferative Glomerulonephritis. , 2008, , 269-289.		0
141	Complement Factor H in Human Platelets: Implications for Atypical HUS.. Blood, 2008, 112, 1833-1833.	1.4	2
142	Deletion of Complement Factor Hâ€“Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome. PLoS Genetics, 2007, 3, e41.	3.5	285
143	Endothelin-1 Induces NF-ÎºB via Two Independent Pathways in Human Renal Tubular Epithelial Cells. American Journal of Nephrology, 2007, 27, 294-300.	3.1	41
144	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	6.1	231

#	Article	IF	Citations
145	Community-acquired pneumonia due to Bordetella holmesii in a patient with frequently relapsing nephrotic syndrome. Journal of Infection, 2007, 54, e203-e205.	3.3	23
146	MPGN II â€“ genetically determined by defective complement regulation?. Pediatric Nephrology, 2007, 22, 2-9.	1.7	37
147	The Role of Defective Complement Control in Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2006, 32, 146-154.	2.7	35
148	Factor H and Atypical Hemolytic Uremic Syndrome: Mutations in the C-Terminus Cause Structural Changes and Defective Recognition Functions. Journal of the American Society of Nephrology: JASN, 2006, 17, 170-177.	6.1	115
149	Detection of Polyomavirus BK and JC in Children With Kidney Diseases and Renal Transplant Recipients. Pediatric Infectious Disease Journal, 2005, 24, 778-781.	2.0	26
150	Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. American Journal of Kidney Diseases, 2005, 45, 415-421.	1.9	113
151	An autocrine role for endothelin-1 in the regulation of proximal tubule NHE3. Kidney International, 2004, 65, 1320-1326.	5.2	36
152	Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney International, 2004, 66, 955-958.	5.2	48
153	Prolonged survival in alveolar capillary dysplasia syndrome. European Journal of Pediatrics, 2004, 163, 181-182.	2.7	40
154	Posttransplant lymphoproliferative disease in a child: clinical and molecular characterization. Pediatric Nephrology, 2002, 17, 79-84.	1.7	2
155	Response to the Letter to the Editor â€œ The apparent beneficial effect of L-arginine for stroke-like lesions can be accidental â€œ by Josef Finsterer and Sinda Zarrouk. Neurohospitalist, The, 0, , 194187442210902.	0.8	0